Ceragenix Pharmaceuticals, Inc., a medical device company focused on infectious disease and dermatology, announced that it has entered into an exclusive distribution and supply agreement with BexPharm Pharmaceuticals, Inc. to commercialize EpiCeram, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in South Korea (the Territory).

The agreement grants BexPharm exclusivity in the Territory for the distribution and marketing of EpiCeram while Ceragenix will be responsible for the manufacturing and supply of the product. BexPharm is also responsible for obtaining regulatory clearance to market EpiCeram in the Territory. Financial terms were not disclosed.

Steven Porter, chairman and chief executive officer of Ceragenix, said, "We are very pleased to expand our Asian footprint for EpiCeram by partnering with BexPharm. BexPharm's management team and capabilities are impressive and we have a shared vision for the product. We expect South Korea to be a very strong market for EpiCeram given the strength of our partner and the prevalence of eczema in the country."

Gye-Bum Yoon, president & CEO of BexPharm, said, "EpiCeram is the exact type of proprietary product which BexPharm is pursuing to make the best use of our existing network of specialists with major hospitals in Korea. We expect that EpiCeram will be an excellent alternative to existing treatments as a non-steroidal atopic dermatitis (AD) treatment product for mild and moderate patients. We believe that EpiCeram can take a significant market share in Korea, which is US$ 50 million with 20% annual growth."

EpiCeram is a topical cream that utilizes Ceragenix's Barrier Repair Technology. In April 2006, the FDA provided clearance to market EpiCeram to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis (eczema), irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment. All of these conditions are associated with a deficient skin barrier function.

Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The company has two base technology platforms; Ceragenins or (CSAs) for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others.

BexPharm Pharmaceuticals Inc. specializes in selling specialty products for dermatology, gastroenterology and interventional radiology in Korea.